Vitamin D supplementation in chronic obstructive pulmonary disease patients with low serum vitamin D: a randomized controlled trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The researchers aimed to assess the effect of vitamin D supplementation on exacerbation rate in vitamin D-deficient patients with COPD.

Why It Was Studied

Vitamin D deficiency is frequently found in patients with chronic obstructive pulmonary disease (COPD).

Vitamin D has antimicrobial, anti-inflammatory, and immunomodulatory effects.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

More than one site took part, so the participants came from several places.

The researchers performed a multicenter, double-blind, randomized controlled trial.

Primary outcome of the study was exacerbation rate.

Secondary outcomes included time to first and second exacerbations, time to first and second hospitalizations, use of antibiotics and corticosteroids, pulmonary function, maximal respiratory mouth pressure, physical performance, skeletal muscle strength, systemic inflammatory markers, nasal microbiota composition, and quality of life.

What Was Measured

The subject headings attached to it are Cholecalciferol, Dietary Supplements, Pulmonary Disease, Chronic Obstructive, Quality of Life, Vitamin D and Vitamin D Deficiency.

Author keywords: chronic obstructive pulmonary disease, exacerbation rate, muscle strength, physical function and pulmonary function.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (The American journal of clinical nutrition), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.